Literature DB >> 29129827

Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation.

Lu-Chen Weng1,2, Sarah R Preis3,4, Olivia L Hulme1,2, Martin G Larson3,4, Seung Hoan Choi2, Biqi Wang3, Ludovic Trinquart3,4, David D McManus5, Laila Staerk4,6, Honghuang Lin4,7, Kathryn L Lunetta3,4, Patrick T Ellinor1,8,2, Emelia J Benjamin4,9, Steven A Lubitz10,8,2.   

Abstract

BACKGROUND: The long-term probability of developing atrial fibrillation (AF) considering genetic predisposition and clinical risk factor burden is unknown.
METHODS: We estimated the lifetime risk of AF in individuals from the community-based Framingham Heart Study. Polygenic risk for AF was derived using a score of ≈1000 AF-associated single-nucleotide polymorphisms. Clinical risk factor burden was calculated for each individual using a validated risk score for incident AF comprised of height, weight, systolic and diastolic blood pressure, current smoking status, antihypertensive medication use, diabetes mellitus, history of myocardial infarction, and history of heart failure. We estimated the lifetime risk of AF within tertiles of polygenic and clinical risk.
RESULTS: Among 4606 participants without AF at 55 years of age, 580 developed incident AF (median follow-up, 9.4 years; 25th-75th percentile, 4.4-14.3 years). The lifetime risk of AF >55 years of age was 37.1% and was substantially influenced by both polygenic and clinical risk factor burden. Among individuals free of AF at 55 years of age, those in low-polygenic and clinical risk tertiles had a lifetime risk of AF of 22.3% (95% confidence interval, 15.4-9.1), whereas those in high-risk tertiles had a risk of 48.2% (95% confidence interval, 41.3-55.1). A lower clinical risk factor burden was associated with later AF onset after adjusting for genetic predisposition (P<0.001).
CONCLUSIONS: In our community-based cohort, the lifetime risk of AF was 37%. Estimation of polygenic AF risk is feasible and together with clinical risk factor burden explains a substantial gradient in long-term AF risk.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; epidemiology; genetics; lifetime risk; polygenic risk; risk factor; risk stratification

Mesh:

Substances:

Year:  2017        PMID: 29129827      PMCID: PMC5840011          DOI: 10.1161/CIRCULATIONAHA.117.031431

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

1.  Epidemiological approaches to heart disease: the Framingham Study.

Authors:  T R DAWBER; G F MEADORS; F E MOORE
Journal:  Am J Public Health Nations Health       Date:  1951-03

2.  The Deceptive Appeal of Direct-to-Consumer Genetics.

Authors:  Wylie Burke; Susan Brown Trinidad
Journal:  Ann Intern Med       Date:  2016-03-01       Impact factor: 25.391

3.  Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.

Authors:  Michael H Kim; Stephen S Johnston; Bong-Chul Chu; Mehul R Dalal; Kathy L Schulman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-05-03

4.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

5.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease.

Authors:  Amit V Khera; Connor A Emdin; Isabel Drake; Pradeep Natarajan; Alexander G Bick; Nancy R Cook; Daniel I Chasman; Usman Baber; Roxana Mehran; Daniel J Rader; Valentin Fuster; Eric Boerwinkle; Olle Melander; Marju Orho-Melander; Paul M Ridker; Sekar Kathiresan
Journal:  N Engl J Med       Date:  2016-11-13       Impact factor: 91.245

6.  Genotype score in addition to common risk factors for prediction of type 2 diabetes.

Authors:  James B Meigs; Peter Shrader; Lisa M Sullivan; Jarred B McAteer; Caroline S Fox; Josée Dupuis; Alisa K Manning; Jose C Florez; Peter W F Wilson; Ralph B D'Agostino; L Adrienne Cupples
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

7.  Genetic Risk Prediction of Atrial Fibrillation.

Authors:  Steven A Lubitz; Xiaoyan Yin; Henry J Lin; Matthew Kolek; J Gustav Smith; Stella Trompet; Michiel Rienstra; Natalia S Rost; Pedro L Teixeira; Peter Almgren; Christopher D Anderson; Lin Y Chen; Gunnar Engström; Ian Ford; Karen L Furie; Xiuqing Guo; Martin G Larson; Kathryn L Lunetta; Peter W Macfarlane; Bruce M Psaty; Elsayed Z Soliman; Nona Sotoodehnia; David J Stott; Kent D Taylor; Lu-Chen Weng; Jie Yao; Bastiaan Geelhoed; Niek Verweij; Joylene E Siland; Sekar Kathiresan; Carolina Roselli; Dan M Roden; Pim van der Harst; Dawood Darbar; J Wouter Jukema; Olle Melander; Jonathan Rosand; Jerome I Rotter; Susan R Heckbert; Patrick T Ellinor; Alvaro Alonso; Emelia J Benjamin
Journal:  Circulation       Date:  2016-10-28       Impact factor: 39.918

8.  UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.

Authors:  Cathie Sudlow; John Gallacher; Naomi Allen; Valerie Beral; Paul Burton; John Danesh; Paul Downey; Paul Elliott; Jane Green; Martin Landray; Bette Liu; Paul Matthews; Giok Ong; Jill Pell; Alan Silman; Alan Young; Tim Sprosen; Tim Peakman; Rory Collins
Journal:  PLoS Med       Date:  2015-03-31       Impact factor: 11.069

9.  Second-generation PLINK: rising to the challenge of larger and richer datasets.

Authors:  Christopher C Chang; Carson C Chow; Laurent Cam Tellier; Shashaank Vattikuti; Shaun M Purcell; James J Lee
Journal:  Gigascience       Date:  2015-02-25       Impact factor: 6.524

10.  A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study.

Authors:  Ingrid E Christophersen; Xiaoyan Yin; Martin G Larson; Steven A Lubitz; Jared W Magnani; David D McManus; Patrick T Ellinor; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-05-17       Impact factor: 4.749

View more
  69 in total

Review 1.  Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond.

Authors:  Carolina Roselli; Michiel Rienstra; Patrick T Ellinor
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 3.  Population-Based Screening for Atrial Fibrillation.

Authors:  Shaan Khurshid; Jeffrey S Healey; William F McIntyre; Steven A Lubitz
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

4.  Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation.

Authors:  M Benjamin Shoemaker; Daniela Husser; Carolina Roselli; Meelad Al Jazairi; Jonathan Chrispin; Michael Kühne; Benjamin Neumann; Stacey Knight; Han Sun; Sanghamitra Mohanty; Christian Shaffer; Sébastien Thériault; Lauren Lee Rinke; Joylene E Siland; Diane M Crawford; Laura Ueberham; Omeed Zardkoohi; Petra Büttner; Bastiaan Geelhoed; Steffen Blum; Stefanie Aeschbacher; Jonathan D Smith; David R Van Wagoner; Rebecca Freudling; Martina Müller-Nurasyid; Jay Montgomery; Zachary Yoneda; Quinn Wells; Tariq Issa; Peter Weeke; Victoria Jacobs; Isabelle C Van Gelder; Gerhard Hindricks; John Barnard; Hugh Calkins; Dawood Darbar; Greg Michaud; Stefan Kääb; Patrick Ellinor; Andrea Natale; Mina Chung; Saman Nazarian; Michael J Cutler; Moritz F Sinner; David Conen; Michiel Rienstra; Andreas Bollmann; Dan M Roden; Steven Lubitz
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-02-14

5.  Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals.

Authors:  Nathan E Wineinger; Paddy M Barrett; Yunyue Zhang; Ikram Irfanullah; Evan D Muse; Steven R Steinhubl; Eric J Topol
Journal:  Heart Rhythm       Date:  2018-08-14       Impact factor: 6.343

6.  Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank.

Authors:  Seung Hoan Choi; Sean J Jurgens; Lu-Chen Weng; James P Pirruccello; Carolina Roselli; Mark Chaffin; Christina J-Y Lee; Amelia W Hall; Amit V Khera; Kathryn L Lunetta; Steven A Lubitz; Patrick T Ellinor
Journal:  Circ Res       Date:  2019-11-06       Impact factor: 17.367

Review 7.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

8.  Is delayed cardioversion the better approach in recent-onset atrial fibrillation? No.

Authors:  Alessandro Capucci; Paolo Compagnucci
Journal:  Intern Emerg Med       Date:  2019-11-13       Impact factor: 3.397

9.  Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-31

10.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.